
FDA pauses schizophrenia trial after patient death
The US Food and Drug Administration (FDA) has paused a trial evaluating a drug for treatment-resistant schizophrenia (TRS) after the death of a participant. Evenamide, developed by biopharmaceutical company Newron Pharmaceuticals, was being evaluated in the Phase III ENIGMA-TRS 2 study, targeting the modulation of excessive release of glutamate in… Read More





